The American Diabetes Association (ADA) guidelines recognize GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes who require additional glucose-lowering therapy beyond metformin, particularly those with established cardiovascular disease or chronic kidney disease, with preference given to agents with proven cardiovascular benefit
Individual results vary and depend on dose, time, and biology
Confirm identity is supported by LC-MS or mass spectrometry
Purified Water, Ammonium Lauryl Sulfate, Glycerin, 1,2-hexanediol, Lauryl Glucoside, Cocamidopropyl Betaine, Acrylate/c10-30 Alkyl Acrylate Crosspolymer, Hydrolyzed Sodium Hyaluronate (9,740 ppm), Tromethamine, Sodium Chloride, Citric Acid, Sodium Benzoate, Glutathione (300 ppm), Disodium Edta, Hydrogenated Lecithin, Maltodextrin, Polyglyceryl-10 Stearate, Polyglyceryl-4 Caprate, Hydrolyzed Gardenia Extract, Butylene Glycol, Niacinamide, Glyceryl Glucoside, White Thistle Extract, Dimethylsilanol Hyaluronate (300 ppb), Sodium Hyaluronate (200 ppb), Polyglyceride Lil-10 Laurate, Hyaluronic Acid (50ppb), Hydrolyzed Hyaluronic Acid (50 ppb), Hydroxypropyltrimonium Hyaluronate (50 ppb), Potassium Hyaluronate (35 ppb), Copper Tripeptide-1, Sodium Acetylated Hyaluronate (15ppb), Acetyl Hexapeptide-8, Cyanocobalamin, Pyridoxine Hcl, Palmitoyl Pentapeptide-4, Palmitoyl Tetrapeptide-7, Palmitoyl Tri Peptide-1, Riboflavin, Fragrance, Hexylcinnamal
PubMed PMID: 11459660
